# Bionano Genomics, Inc.: financial statements, quarterly

BNGO · Nasdaq · CIK 1411690 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bngo.md) · [Financials](/companies/bngo/financials.md) · [Filings](/companies/bngo/filings.md) · [Insiders](/companies/bngo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bngo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [9.3](/filings/0001411690-24-000063.md) | [10.7 d](/filings/0001411690-25-000037.md) | [8.8](/filings/0001411690-25-000046.md) | [7.8](/filings/0001411690-25-000083.md) | [6.1](/filings/0001411690-25-000093.md) | [8.2 d](/filings/0001411690-26-000007.md) | [6.5](/filings/0001411690-26-000028.md) | [6.7](/filings/0001411690-26-000044.md) | [7.4](/filings/0001411690-25-000093.md) | [8.0 d](/filings/0001411690-26-000007.md) | [6.7](/filings/0001411690-26-000028.md) | [8.2](/filings/0001411690-26-000044.md) |
| Cost of revenue | $m | [6.6](/filings/0001411690-24-000063.md) | [8.3 d](/filings/0001411690-25-000037.md) | [5.9](/filings/0001411690-25-000046.md) | [5.2](/filings/0001411690-25-000083.md) | [14.5](/filings/0001411690-25-000093.md) | [4.7 d](/filings/0001411690-26-000007.md) | [3.5](/filings/0001411690-26-000028.md) | [3.3](/filings/0001411690-26-000044.md) | [4.0](/filings/0001411690-25-000093.md) | [4.6 d](/filings/0001411690-26-000007.md) | [3.4](/filings/0001411690-26-000028.md) | [3.9](/filings/0001411690-26-000044.md) |
| Research and development | $m | [13.8](/filings/0001411690-24-000063.md) | [11.7 d](/filings/0001411690-25-000037.md) | [9.8](/filings/0001411690-25-000046.md) | [6.8](/filings/0001411690-25-000083.md) | [4.7](/filings/0001411690-25-000093.md) | [3.5 d](/filings/0001411690-26-000007.md) | [2.4](/filings/0001411690-26-000028.md) | [2.9](/filings/0001411690-26-000044.md) | [2.8](/filings/0001411690-25-000093.md) | [3.2 d](/filings/0001411690-26-000007.md) | [3.1](/filings/0001411690-26-000028.md) | [3.0](/filings/0001411690-26-000044.md) |
| Selling, general and administrative | $m | [24.9](/filings/0001411690-24-000063.md) | [14.9 d](/filings/0001411690-25-000037.md) | [19.1](/filings/0001411690-25-000046.md) | [11.6](/filings/0001411690-25-000083.md) | [9.5](/filings/0001411690-25-000093.md) | [11.7 d](/filings/0001411690-26-000007.md) | [9.0](/filings/0001411690-26-000028.md) | [8.3](/filings/0001411690-26-000044.md) | [9.1](/filings/0001411690-25-000093.md) | [8.7 d](/filings/0001411690-26-000007.md) | [8.0](/filings/0001411690-26-000028.md) | [8.5](/filings/0001411690-26-000044.md) |
| Operating income | $m | [(113)](/filings/0001411690-24-000063.md) | [(25.0) d](/filings/0001411690-25-000037.md) | [(31.1)](/filings/0001411690-25-000046.md) | [(17.0)](/filings/0001411690-25-000083.md) | [(43.9)](/filings/0001411690-25-000093.md) | [(11.9) d](/filings/0001411690-26-000007.md) | [(8.5)](/filings/0001411690-26-000028.md) | [(7.8)](/filings/0001411690-26-000044.md) | [(8.5)](/filings/0001411690-25-000093.md) | [(8.5) d](/filings/0001411690-26-000007.md) | [(7.9)](/filings/0001411690-26-000028.md) | [(7.2)](/filings/0001411690-26-000044.md) |
| Interest expense | $m | [0.1](/filings/0001411690-23-000082.md) | [4.9 d](/filings/0001411690-24-000013.md) | [0.1](/filings/0001411690-24-000021.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001411690-24-000063.md) | [(0.0) d](/filings/0001411690-25-000037.md) | [(0.0)](/filings/0001411690-25-000046.md) | [0.0](/filings/0001411690-25-000083.md) | [0.0](/filings/0001411690-25-000093.md) | [0.0 d](/filings/0001411690-26-000007.md) | [0.0](/filings/0001411690-26-000028.md) | [0.0](/filings/0001411690-26-000044.md) | [0.0](/filings/0001411690-25-000093.md) | [0.0 d](/filings/0001411690-26-000007.md) | [0.0](/filings/0001411690-26-000028.md) | [0.0](/filings/0001411690-26-000044.md) |
| Net income | $m | [(113)](/filings/0001411690-24-000063.md) | [(43.9) d](/filings/0001411690-25-000037.md) | [(31.4)](/filings/0001411690-25-000093.md) | [(16.2)](/filings/0001411690-25-000093.md) | [(44.2)](/filings/0001411690-25-000093.md) | [(20.1) d](/filings/0001411690-26-000007.md) | [(3.1)](/filings/0001411690-26-000044.md) | [(6.9)](/filings/0001411690-26-000044.md) | [(8.5)](/filings/0001411690-25-000093.md) | [(7.9) d](/filings/0001411690-26-000007.md) | [(8.3)](/filings/0001411690-26-000044.md) | [(7.4)](/filings/0001411690-26-000044.md) |
| Diluted EPS | $ per share | [(3.22)](/filings/0001411690-24-000063.md) | not reported | [(35.75)](/filings/0001411690-25-000046.md) | [(14.41)](/filings/0001411690-25-000083.md) | [(30.92)](/filings/0001411690-25-000093.md) | not reported | [(1.15)](/filings/0001411690-26-000028.md) | [(1.99)](/filings/0001411690-26-000044.md) | [(1.59)](/filings/0001411690-25-000093.md) | not reported | [(0.76)](/filings/0001411690-26-000028.md) | [(0.64)](/filings/0001411690-26-000044.md) |
| Basic EPS | $ per share | [(3.22)](/filings/0001411690-24-000063.md) | not reported | [(35.75)](/filings/0001411690-25-000046.md) | [(14.41)](/filings/0001411690-25-000083.md) | [(30.92)](/filings/0001411690-25-000093.md) | not reported | [(1.15)](/filings/0001411690-26-000028.md) | [(1.99)](/filings/0001411690-26-000044.md) | [(1.59)](/filings/0001411690-25-000093.md) | not reported | [(0.76)](/filings/0001411690-26-000028.md) | [(0.64)](/filings/0001411690-26-000044.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [34.6](/filings/0001411690-24-000063.md) | [17.9](/filings/0001411690-25-000037.md) | [15.8](/filings/0001411690-25-000046.md) | [10.4](/filings/0001411690-25-000083.md) | [8.8](/filings/0001411690-25-000093.md) | [9.2](/filings/0001411690-26-000007.md) | [3.6](/filings/0001411690-26-000028.md) | [3.6](/filings/0001411690-26-000044.md) | [3.1](/filings/0001411690-25-000093.md) | [3.0](/filings/0001411690-26-000044.md) | [3.4](/filings/0001411690-26-000028.md) | [3.7](/filings/0001411690-26-000044.md) |
| Current assets | $m | [105](/filings/0001411690-23-000082.md) | [140](/filings/0001411690-25-000037.md) | [85.6](/filings/0001411690-24-000021.md) | [60.6](/filings/0001411690-24-000049.md) | [47.0](/filings/0001411690-24-000063.md) | [39.5](/filings/0001411690-26-000007.md) | [44.9](/filings/0001411690-25-000046.md) | [42.7](/filings/0001411690-25-000083.md) | [48.8](/filings/0001411690-25-000093.md) | [45.4](/filings/0001411690-26-000044.md) | [39.0](/filings/0001411690-26-000028.md) | [24.9](/filings/0001411690-26-000044.md) |
| Total assets | $m | [182](/filings/0001411690-23-000082.md) | [214](/filings/0001411690-25-000037.md) | [158](/filings/0001411690-24-000021.md) | [129](/filings/0001411690-24-000049.md) | [87.4](/filings/0001411690-24-000063.md) | [76.7](/filings/0001411690-26-000007.md) | [78.4](/filings/0001411690-25-000046.md) | [76.0](/filings/0001411690-25-000083.md) | [79.1](/filings/0001411690-25-000093.md) | [73.6](/filings/0001411690-26-000044.md) | [64.8](/filings/0001411690-26-000028.md) | [47.6](/filings/0001411690-26-000044.md) |
| Current liabilities | $m | [40.2](/filings/0001411690-23-000082.md) | [100](/filings/0001411690-25-000037.md) | [58.5](/filings/0001411690-24-000021.md) | [37.2](/filings/0001411690-24-000049.md) | [33.0](/filings/0001411690-24-000063.md) | [37.3](/filings/0001411690-26-000007.md) | [26.4](/filings/0001411690-25-000046.md) | [24.2](/filings/0001411690-25-000083.md) | [23.0](/filings/0001411690-25-000093.md) | [22.9](/filings/0001411690-26-000044.md) | [21.2](/filings/0001411690-26-000028.md) | [10.0](/filings/0001411690-26-000044.md) |
| Total liabilities | $m | [62.9](/filings/0001411690-23-000082.md) | [118](/filings/0001411690-25-000037.md) | [75.2](/filings/0001411690-24-000021.md) | [49.0](/filings/0001411690-24-000049.md) | [38.5](/filings/0001411690-24-000063.md) | [41.3](/filings/0001411690-26-000007.md) | [30.2](/filings/0001411690-25-000046.md) | [30.6](/filings/0001411690-25-000083.md) | [29.3](/filings/0001411690-25-000093.md) | [29.2](/filings/0001411690-26-000044.md) | [27.3](/filings/0001411690-26-000028.md) | [16.0](/filings/0001411690-26-000044.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [119](/filings/0001411690-24-000063.md) | [96.2](/filings/0001411690-26-000007.md) | [82.8](/filings/0001411690-25-000093.md) | [80.3](/filings/0001411690-25-000093.md) | [48.9](/filings/0001411690-25-000093.md) | [35.4](/filings/0001411690-26-000044.md) | [48.2](/filings/0001411690-26-000044.md) | [45.4](/filings/0001411690-26-000044.md) | [49.8](/filings/0001411690-25-000093.md) | [44.4](/filings/0001411690-26-000044.md) | [37.5](/filings/0001411690-26-000044.md) | [31.6](/filings/0001411690-26-000044.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(26.3) d](/filings/0001411690-24-000063.md) | [(29.8) d](/filings/0001411690-25-000037.md) | [(28.1)](/filings/0001411690-25-000046.md) | [(21.0) d](/filings/0001411690-25-000083.md) | [(13.3) d](/filings/0001411690-25-000093.md) | [(6.5) d](/filings/0001411690-26-000007.md) | [(2.8)](/filings/0001411690-26-000028.md) | [(3.5) d](/filings/0001411690-26-000044.md) | [(5.9) d](/filings/0001411690-25-000093.md) | [(4.2) d](/filings/0001411690-26-000007.md) | [(5.7)](/filings/0001411690-26-000028.md) | [(4.7) d](/filings/0001411690-26-000044.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.0](/filings/0001411690-23-000082.md) | [30.2](/filings/0001411690-24-000021.md) | [31.5](/filings/0001411690-24-000049.md) | [35.0](/filings/0001411690-24-000063.md) | [0.9](/filings/0001411690-25-000046.md) | [1.1](/filings/0001411690-25-000083.md) | [1.4](/filings/0001411690-25-000093.md) | [2.7](/filings/0001411690-26-000028.md) | [3.4](/filings/0001411690-26-000044.md) | [5.3](/filings/0001411690-25-000093.md) | [11.0](/filings/0001411690-26-000028.md) | [11.5](/filings/0001411690-26-000044.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 11,777,000 at 2026-08-06, from the cover of the [10-Q filed 2026-08-10](/filings/0001411690-26-000044.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.